Results 31 to 40 of about 2,265,539 (159)

Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75.

Endocrinology, 1990
Membrane receptors for LHRH were evaluated in Dunning R3327 prostate cancers and rat anterior pituitaries. The receptors were characterized both in untreated animals and after in vivo treatment with microcapsules of the agonist D-Trp6-LHRH and a ...
G. Srkalović, L. Bokser, S. Radulović, E. Korkut, A. Schally   +4 more
semanticscholar   +1 more source

The contemporary management of prostate cancer

CA: A Cancer Journal for Clinicians, EarlyView.
Abstract Prostate cancer is the most common cancer in two thirds of the world, with an expected doubling in both incidence and mortality in the next two decades. No strong environmental associations exist for the development of prostate cancer; therefore, lifestyle measures are unlikely to mitigate this increasing burden.
Deep Chakrabarti, Peter Albertsen, Aidan Adkins, Amar Kishan, Vedang Murthy, Chris Parker, Angela Pathmanathan, Alison Reid, Oliver Sartor, Nicholas Van As, Jochen Walz, Alison Tree   +11 more
wiley   +1 more source

Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable‐Intermediate and High‐Risk Prostate Cancer

The Prostate, Volume 85, Issue 10, Page 977-985, July 2025.
ABSTRACT Background Standard treatment for unfavorable‐intermediate and high‐risk prostate cancer involves androgen deprivation therapy (ADT) in combination with pelvic conventional fractionation (CF) external beam radiotherapy (EBRT) and a CF‐EBRT or brachytherapy boost to the prostate.
Andre Gouveia, Aruz Mesci, Naghmeh Isfahanian, Ian Dayes, Kimmen Quan, Mira Goldberg, Kara Lynne Schnarr, Himu Lukka, David Cuthbert, Abhiram Hallock, Georgia Douvi, Jim Wright, Anand Swaminath, Tom Chow, Kevin Diamond, George Hajdok, Lindsay Maharaj, Joycelyne Ewusie, Theodoros Tsakiridis   +18 more
wiley   +1 more source

Effects of an LHRH agonist on endocrine function, LHRH receptor and LH/hCG receptor in the pituitary-gonadal axis of male rats.

Endocrinologia Japonica, 1986
The effects of an LHRH agonist (LHRHa), [D-Ser (tBu)]6 des-Gly-NH210) ethylamide, on endocrine function and the LHRH and LH/hCG receptors in the pituitary-gonadal axis were examined. The LHRHa was injected at 100 ng/100 g body weight into male rats once a day for 4 weeks and its effects were observed until 2 weeks after the end of treatment.
Shinji Mitsuhashi, Hiroyuki Iwahana, Machiko Komatsu   +2 more
openaire   +4 more sources

Clinical evaluation and outcome in heart failure patients receiving chemotherapy with different anti‐cancer agents

ESC Heart Failure, Volume 12, Issue 3, Page 1965-1976, June 2025.
Abstract Background The optimal strategy for modern chemotherapy should be based on a comprehensive approach for cancer patients with cardiovascular diseases. Therefore, cardio‐oncology has received increasing attention owing to the cardiotoxic effects of anti‐cancer therapies.
Tomiko Sunaga, Takahiro Okada, Yoshitaka Iso, Mio Ebato, Tsutomu Toshida, Shuichi Nawata, Hiroshi Suzuki, Mari Kogo   +7 more
wiley   +1 more source

Androgen Deprivation Therapy–Induced Muscle Loss and Fat Gain Predict Cardiovascular Events in Prostate Cancer Patients

Journal of Cachexia, Sarcopenia and Muscle, Volume 16, Issue 3, June 2025.
ABSTRACT Background Androgen deprivation therapy (ADT) increases the risk of adverse cardiovascular events in patients with prostate cancer. ADT can induce body composition change; however, the association between body composition change and cardiovascular outcomes remains unclear.
Jie Lee, Yi‐Hsuan Lin, Pai‐Kai Chiang, Jhen‐Bin Lin, Ya‐Ting Jan, Wei‐Kung Tsai, Yu‐Jen Chen, Kun‐Pin Wu   +7 more
wiley   +1 more source

Blockade of central and peripheral luteinizing hormone-releasing hormone (LHRH) receptors in neonatal rats with a potent LHRH-antagonist inhibits the morphofunctional development of the thymus and maturation of the cell-mediated and humoral immune responses.

Endocrinology, 1991
The development of the thymus and the hypothalamic-pituitary-gonadal axis are linked by bidirectional hormonally mediated relationships. In the present study, the direct involvement of the neuropeptide LHRH in the maturation of the thymus and development
M. C. Morale, N. Batticane, G. Bartoloni, V. Guarcello, Z. Farinella, M. G. Galasso, Bianca Marchetti   +6 more
semanticscholar   +1 more source

Systematic Review and Meta‐Analysis on the Prevalence of Radiotherapy‐Induced Hypopituitarism in Adults With Primary Non‐Pituitary Brain Tumours

Clinical Endocrinology, Volume 102, Issue 6, Page 683-698, June 2025.
ABSTRACT Context It is well recognised there is a high prevalence of pituitary dysfunction in childhood brain tumours survivors who are treated with radiotherapy. In contrast, the potential for survivors of brain tumours arising in adulthood to develop radiotherapy‐induced hypopituitarism may be underestimated.
Darran Mc Donald, Maria Tomkins, Liam O'Connell, David Fitzpatrick, Clare Faul, Michael W. O'Reilly, Kathleen Bennett, Mark Sherlock   +7 more
wiley   +1 more source

Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes

International Journal of Nanomedicine, 2010
Yingna He, Linhua Zhang, Cunxian SongKey Laboratory of Biomedical Material of Tianjin, Institute of Biomedical Engineering, Peking Union Medical College and Chinese Academy of Medical Sciences, Tianjin, ChinaAbstract: A sterically stabilized ...
Yingna He, Linhua Zhang, Cunxian Song
doaj  

Bone Health Management in Men Commencing Androgen Deprivation Therapy for Prostate Cancer and Women Commencing Anti‐Oestrogen Therapy for Breast Cancer

Cancer Medicine, Volume 14, Issue 9, May 2025.
ABSTRACT Background Survival of patients with prostate and breast cancer, the commonest cancer in men and women, respectively, has markedly improved with advances in early diagnosis, treatment and multi‐disciplinary care by the oncology and surgical community. However, the use of increasingly potent endocrine therapies may cause bone loss, resulting in
Ian Liang, Sarah Brennan, Christian Girgis, Amy Hayden, Tania Moujaber, Sandra Turner, Anuradha Vasista, Mathis Grossmann, Peter K. K. Wong   +8 more
wiley   +1 more source